BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk...

Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

July 19 2018 Cochrane researchers have published research indicating that omega 3 supplements...

DOACs associated with reduced risk of major bleeding compared to warfarin

DOACs associated with reduced risk of major bleeding compared to warfarin

July 11 2018 Direct oral anticoagulants (DOACs) have been associated with reduced risks of major...

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

July 3 2018 People who have a record of penicillin allergy are at an increased risk of developing...

MPS advises of need for better awareness of cauda equina red flag symptoms

MPS advises of need for better awareness of cauda equina red flag symptoms

May 9 2018 The Medical Protection Society is advising doctors of a revision to the NICE Clinical...

  • BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

    BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

    Wednesday, 25 July 2018 14:07
  • Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

    Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

    Thursday, 19 July 2018 10:36
  • DOACs associated with reduced risk of major bleeding compared to warfarin

    DOACs associated with reduced risk of major bleeding compared to warfarin

    Wednesday, 11 July 2018 13:22
  • Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Tuesday, 03 July 2018 16:51
  • MPS advises of need for better awareness of cauda equina red flag symptoms

    MPS advises of need for better awareness of cauda equina red flag symptoms

    Wednesday, 09 May 2018 16:01

A pregnant lady imageFebruary 28 2018

The Government has launched a review into how the NHS responds to reports from patients about side effects from treatments.

It will consider three treatments that have had been brought to prominence through patient-led campaigns: 

  • sodium valproate;
  • the Primodos hormone pregnancy test, which was used up until 1978;
  • the use of vaginal mesh.

Announcing the review, Health Secretary Jeremy Hunt said: “Over the years, there have been significant concerns raised by individuals and campaign groups about the potentially harmful effects of three products used by the NHS. The response they have received from those in positions of authority has not always been good enough.

“From Primodos to mesh and sodium valproate, patients and their families have had to spend too much time and energy campaigning for answers in a way that has added insult to injury for many. I want to see if we can establish a fairer and quicker way of resolving these concerns both now and in the future.”

Former health minister Baroness Cumberlege will chair the review. She has been asked to consider:

  • whether any further action is needed relating to the complaints around Primodos, sodium valproate and vaginal mesh;
  • the processes followed by the NHS and its regulators when patients report a problem;
  • how to make sure communication between the different groups involved is good.

Baroness Cumberlege, said: “It’s essential that voices aren’t just listened to, but properly heard, and that whenever appropriate, the system promptly learns lessons and makes changes.”

Epilepsy Action’s deputy chief executive Simon Wigglesworth commented: “Today’s announcement marks a major breakthrough for the thousands of women with epilepsy who’ve campaigned for change around sodium valproate.

“We urge Baroness Cumberlege to fully consider the decades of evidence provided by campaigning groups, including Epilepsy Action. This will help those families who’ve suffered can get some closure. It will also help women with epilepsy make fully-informed decisions about their treatment and planning a family.”

Links:
Department of Health and Social Care announcement  
Epilepsy Action statement       

Clinical News

July 27 2018 Adolescent boys will be offered the human papilloma virus (HPV) vaccine to protect them from cancer, the Department of Health and Social Care has announced.
July 20 2018 Doctors are being reminded to ensure that any patient or other records which may be relevant to the UK Infected Blood Inquiry are not destroyed. Earlier this month, the Inquiry’s Chair, Sir...